logo
← Back to RNS Announcements

IBT INTERIM RESULTS

I am able to report a rise in both the Net Asset Value per share ("NAV") and the share price of the Company over the half year to 28th February 2011. The NAV increased by 7.5% to 166.8 pence, which compares with 14.4% and 18.5% increases in the NASDAQ Biotechnology Index ("NBI") and the Russell 2000 Biotech Index ("RGUHSBTG") (both adjusted for the change in the Sterling/Dollar exchange rate). Broader stock markets - as measured by the FTSE All-Share index (UK) and the S&P500 index (US) - rose by 15.2% and 19.4% (the latter exchange-rate adjusted).

Published on 15th April 2011

Science background with molecule or atom Abstract structure for Science or medical background
Science background with molecule or atom Abstract structure for Science or medical background

Disclaimer

The information on this website may only be suitable for certain types of investors and is not intended to be used or relied upon by any other person.

An investment with IBT may contain significant risks and is intended only for sophisticated investors who meet certain eligibility criteria.

The material on this website is intended to be viewed only by persons resident in the EEA.

The information on this website is not an offer to sell or a solicitation of an offer and does not constitute investment advice.

No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained therein.

The information on this website may constitute financial promotion for the purposes of the Financial Services and Markets Act 2000 (“FSMA”).


I do not accept →